健康的生活方式是预防中度和重度复发以及在炎症性肠病中使用类固醇的保护因素:一项前性队列研究
Sandra García-Mateo1,2, Samuel Jesús Martínez-Domínguez1,2, Carla Jerusalén Gargallo-Puyuelo1,2
1Department of Gastroenterology, Lozano Blesa University Clinical Hospital, 50009 Zaragoza, Spain.
Inflammatory bowel diseases
|March 23, 2024
概括
健康的生活方式,包括遵守地中海饮食和身体活动,可以显著降低炎症性肠病 (IBD) 复发的风险和严重程度. 这种方法应该成为IBD患者管理的组成部分,以缓和的疾病过程.
科学领域:
- 胃肠病学 胃肠病学
- 慢性疾病管理 慢性疾病管理
- 生活方式 医学 医疗
背景情况:
- 炎症性肠病 (IBD) 的过程可能受到生活方式因素的影响.
- 地中海饮食 (MD) 和体力活动是健康生活方式的关键组成部分.
- 联合MD坚持和身体活动对IBD的影响需要进一步调查.
研究的目的:
- 确定遵守地中海饮食 (MD) 和体力活动是否会影响炎症性肠病 (IBD) 的发展.
- 评估MD和体育活动对IBD复发风险和严重性的综合影响.
主要方法:
- 对693名IBD门诊患者进行前性队列研究.
- 通过患者调查评估MD遵守和身体活动.
- 监测IBD复发,严重程度,类固醇使用和治疗变化在27个月的中位数随访期间.
主要成果:
- 在IBD患者中,健康的生活方式与中度至重度复发的风险明显降低 (aHR 0.250).
- 坚持健康的生活方式也减少了对全身类固醇的需求 (aHR 0.292).
- 与克罗恩病患者相比,性结肠炎患者对健康的生活方式的坚持更强.
结论:
- 健康的生活方式,包括地中海饮食和体育活动,有利于影响较轻微的IBD疾病过程.
- 将健康生活方式建议纳入临床管理对于IBD患者至关重要.
- 这种方法可能有助于减轻复发的严重程度,并减少对皮质类固醇的依赖.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


